Allogene Therapeutics (ALLO) Receivables (2020)

Allogene Therapeutics (ALLO) posted Receivables of $3.1 million for Q3 2020, up 287.5% sequentially from $800000.0 in Q2 2020.

Allogene Therapeutics (ALLO) Receivables (2020) Analysis & Trends

Allogene Therapeutics has reported Receivables for 1 years, with the latest figure at $3.1 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Allogene Therapeutics	707.96 Mn	707.96 Mn	-	-

Download Data